Search

Your search keyword '"FALLET, Vincent"' showing total 145 results

Search Constraints

Start Over You searched for: Author "FALLET, Vincent" Remove constraint Author: "FALLET, Vincent"
145 results on '"FALLET, Vincent"'

Search Results

4. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

5. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study

7. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

8. Real-World Efficacy of the Dabrafenib-Trametinib (D-T) Combination in Braf V600e-Mutated Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Ifct-2004 Blade Cohort

9. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC

10. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

11. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

15. Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells

17. Characterization of lung cancers in patients with BRCA germline variants: A multicenter series

18. Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

20. Abstract 4019: RET-MAP: An international multi-center study of patients with advanced non-small cell lung cancer and RET fusions

22. Efficacy of dabrafenib-trametinib combination in BRAF V600E-mutated metastatic non–small cell lung cancer: Results of the IFCT-2004 BLaDE cohort.

24. Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study

26. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

28. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

29. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC

36. Circulating Tumor Cells as a Potential Biomarker for Lung Cancer Screening: Results of the AIR Study

39. Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)

40. Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer

42. Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

43. Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC)

44. Real-life use of nivolumab in non-small cell lung cancer: A multicentric cohort to determine its clinical efficacy and predictive factors of early progression.

45. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung

50. Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung

Catalog

Books, media, physical & digital resources